Rhea-AI Impact
Rhea-AI Sentiment
Rhea-AI Summary
Elevai Labs Inc. (NASDAQ: ELAB) has announced a 1-for-200 reverse stock split effective November 27, 2024, to maintain Nasdaq listing compliance. The split aims to meet Nasdaq’s minimum bid price requirement of $1.00 per share. After the split, approximately 3.07 million shares will be outstanding. Shareholders will receive one share for every 200 shares held, with fractional shares rounded up to one full share. While the trading symbol remains ‘ELAB’, a new CUSIP number (28622K 203) has been assigned. The split proportionally adjusts outstanding stock awards, options, and equity incentive plans without affecting overall shareholder equity value.
Elevai Labs Inc. (NASDAQ: ELAB) ha annunciato un’operazione di reverse stock split di 1 per 200 che entrerà in vigore il 27 novembre 2024, al fine di mantenere la conformità con le normative di quotazione di Nasdaq. Questa operazione ha come obiettivo quello di soddisfare il requisito di prezzo minimo di offerta di $1,00 per azione di Nasdaq. Dopo lo split, saranno in circolazione circa 3,07 milioni di azioni. Gli azionisti riceveranno un’azione per ogni 200 azioni detenute, con le azioni frazionarie arrotondate a un’azione intera. Sebbene il simbolo di trading rimanga ‘ELAB’, è stato assegnato un nuovo numero CUSIP (28622K 203). Lo split aggiusta proporzionalmente le azioni in circolazione, le opzioni e i piani di incentivi azionari senza influenzare il valore complessivo del capitale azionario degli azionisti.
Elevai Labs Inc. (NASDAQ: ELAB) ha anunciado una agrupación de acciones al revés de 1 por 200 que entrará en vigor el 27 de noviembre de 2024, para mantener la conformidad con los requisitos de cotización de Nasdaq. La agrupación tiene como objetivo cumplir con el requisito de precio mínimo de oferta de $1.00 por acción de Nasdaq. Después de la agrupación, aproximadamente 3.07 millones de acciones estarán en circulación. Los accionistas recibirán una acción por cada 200 acciones que posean, con las acciones fraccionarias redondeadas a una acción completa. Aunque el símbolo de negociación se mantendrá como ‘ELAB’, se ha asignado un nuevo número CUSIP (28622K 203). La agrupación ajusta proporcionalmente las acciones, opciones y planes de incentivos de capital sin afectar el valor total del patrimonio de los accionistas.
Elevai Labs Inc. (NASDAQ: ELAB)는 2024년 11월 27일에 나스닥 상장 준수를 유지하기 위해 1대 200의 자사주 매입을 발표했습니다. 이 매입은 나스닥의 최소 청약 가격 요구 사항인 주당 $1.00을 충족하는 것을 목표로 합니다. 매입 후 약 307만 주가 유통될 것입니다. 주주들은 보유한 200주당 1주를 받게 되며, 분수 주식은 1전체 주식으로 반올림됩니다. 거래 기호는 ‘ELAB’로 유지되지만 새로운 CUSIP 번호(28622K 203)가 부여되었습니다. 이 조치는 전체 주주 자본 가치에 영향을 미치지 않고 유통 주식 보상, 옵션 및 자본 유인 계획을 비례적으로 조정합니다.
Elevai Labs Inc. (NASDAQ: ELAB) a annoncé un regroupement d’actions de 1 pour 200 qui entrera en vigueur le 27 novembre 2024, afin de maintenir la conformité avec les exigences de cotation de Nasdaq. Ce regroupement vise à répondre à l’exigence de prix d’offre minimum de $1,00 par action de Nasdaq. Après le regroupement, environ 3,07 millions d’actions seront en circulation. Les actionnaires recevront une action pour chaque 200 actions détenues, les actions fractionnaires étant arrondies à une action entière. Bien que le symbole de négociation demeure ‘ELAB’, un nouveau numéro CUSIP (28622K 203) a été attribué. Le regroupement ajuste proportionnellement les attributions d’actions en circulation, les options et les plans d’incitation en actions sans affecter la valeur totale du capital des actionnaires.
Elevai Labs Inc. (NASDAQ: ELAB) hat einen Reverse-Split von 1 zu 200 angekündigt, der am 27. November 2024 in Kraft tritt, um die Einhaltung der Nasdaq-Listing-Anforderungen zu gewährleisten. Der Split zielt darauf ab, die Mindestangebotspreisanforderung von Nasdaq von $1,00 pro Aktie zu erfüllen. Nach dem Split werden etwa 3,07 Millionen Aktien im Umlauf sein. Aktionäre erhalten eine Aktie für jede 200 gehaltenen Aktien, wobei Bruchstücke auf eine volle Aktie aufgerundet werden. Während das Handelssymbol ‘ELAB’ bleibt, wurde eine neue CUSIP-Nummer (28622K 203) zugewiesen. Der Split passt die ausgegebenen Aktienauszeichnungen, Optionen und Aktienanreizpläne proportional an, ohne den Gesamtwert des Eigenkapitals der Aktionäre zu beeinträchtigen.
Positive
- No immediate shareholder action required for the reverse split process
- Maintaining Nasdaq listing status preserves market visibility and trading access
Negative
- Implementation of 1-for-200 reverse stock split indicates severe share price decline
- Risk of delisting from Nasdaq due to non-compliance with minimum bid requirements
- Potential negative market perception of reverse stock splits
Insights
The 1-for-200 reverse stock split is a concerning development signaling significant financial distress. With ELAB trading well below $1, this drastic consolidation aims to artificially boost the share price to meet Nasdaq’s minimum listing requirements. The reduction to approximately 3.07 million shares outstanding from over 614 million reflects the severity of the situation. While technically maintaining Nasdaq listing provides better liquidity and visibility, reverse splits historically often precede further price declines as they don’t address fundamental business challenges. The move may temporarily prevent delisting but raises red flags about the company’s financial health and market confidence. Shareholders should note that while their ownership percentage remains unchanged, such extreme consolidation ratios typically indicate elevated risk levels.
NEWPORT BEACH, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) — Elevai Labs Inc. (NASDAQ: ELAB) (Elevai” or the “Company”) announced today it will implement a 1-for-200 reverse stock split (“Reverse Stock Split”) of its common stock, which will be effective at midnight on November 27, 2024. This initiative aligns with the Company’s efforts to meet Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2).
Key Details of the Reverse Stock Split:
– Conversion Ratio: Every 200 shares of issued and outstanding common stock will be automatically consolidated into one share, with no action required from shareholders.
– Fractional Shares: Shareholders entitled to fractional shares will receive one full share for each fractional portion.
– Updated Stock Identifier: While the trading symbol remains “ELAB”, the common stock now carries a new CUSIP number (28622K 203).
– Equity Adjustments: Outstanding stock awards, options, and the equity incentive plan have been adjusted proportionally to reflect the new share structure.
Purpose of the Reverse Stock Split:
The Reverse Stock Split is a critical step in ensuring compliance with Nasdaq’s listing requirements, allowing Elevai to maintain its presence on the Nasdaq Capital Market. A continued listing enhances the Company’s visibility, strengthens investor confidence, and positions Elevai for future growth.
Impact on Shareholders:
– No Immediate Action Required: Shareholders holding shares through a broker or in “street name” will see their holdings updated automatically.
– Certificate Holders: Shareholders with physical certificates can exchange them, if desired, through VStock Transfer, LLC, which will provide detailed instructions.
– Share Value: The Reverse Stock Split does not impact the overall value of shareholder equity; it only reduces the number of shares outstanding while proportionally adjusting the share price.
Impact on our Common Stock:
– Post Reverse Stock Split there will be approximately 3.07 million shares of common stock issued and outstanding
Looking Ahead:
“The reverse stock split is a required measure to preserve Elevai’s Nasdaq listing and set the stage for our continued progress in innovation and shareholder value creation,” said Graydon Bensler, Chief Executive Officer of Elevai. “We are optimistic about the future and committed to executing our growth strategy.”
For additional information, please refer to Elevai’s full Form 8-K filing available regarding the Reverse Stock Split, filed on November 22, 2024, on the SEC’s website, or contact Elevai directly at IR@elevailabs.com.
About Elevai Labs, Inc.
Elevai Labs Inc. (NASDAQ: ELAB) specializes in medical aesthetics and biopharmaceutical drug development, focusing on innovations for skin aesthetics and treatments tied to obesity and metabolic health. The Company operates a diverse portfolio of three wholly owned subsidiaries across the medical aesthetics and biopharmaceutical sectors, Elevai Skincare Inc., Elevai Biosciences Inc., and Elevai Research Inc. For more information please visit www.elevailabs.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “believes,” “expects,” “plans,” “potential,” “would” and “future” or similar expressions such as “look forward” are intended to identify forward-looking statements. Forward-looking statements are made as of the date of this press release and are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. Therefore, you should not rely on any of these forward-looking statements. These and other risks are described more fully in Elevai’s filings with the United States Securities and Exchange Commission (“SEC”), including the “Risk Factors” section of the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, filed with the SEC on March 29, 2024, and its other documents subsequently filed with or furnished to the SEC. Investors and security holders are urged to read these documents free of charge on the SEC’s web site at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Except to the extent required by law, the Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
IR Contact:
IR@ElevaiLabs.com
FAQ
What is the reverse stock split ratio announced by Elevai Labs (ELAB)?
Elevai Labs announced a 1-for-200 reverse stock split effective November 27, 2024.
How many shares of ELAB will be outstanding after the reverse split?
After the reverse stock split, approximately 3.07 million shares of common stock will be outstanding.
Why is Elevai Labs (ELAB) implementing a reverse stock split?
Elevai Labs is implementing the reverse stock split to maintain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2).
What happens to fractional shares in ELAB’s reverse stock split?
Shareholders entitled to fractional shares will receive one full share for each fractional portion.
